Lisata Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 5.99 million compared to USD 6.79 million a year ago. Basic loss per share from continuing operations was USD 0.76 compared to USD 1.7 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.77 USD | -2.62% | -4.91% | +1.47% |
May. 09 | Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.47% | 23.63M | |
+30.75% | 49.46B | |
+1.16% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.78% | 26.61B | |
-23.76% | 18.64B | |
+7.38% | 13.16B | |
+31.42% | 12.55B | |
+23.46% | 12.1B |
- Stock Market
- Equities
- LSTA Stock
- News Lisata Therapeutics, Inc.
- Lisata Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022